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Objective: We compared the effects of 2 sedative drugs, dexmedetomidine and midazolam, on motor
performance and analgesic efﬁcacy in a rat model.Key words:
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Materials and methods: Rats were randomly divided into the following 4 groups on the basis of the
treatment received. The ﬁrst group received 83 mg/kg/min midazolam; the second, 1 mg/kg/min
dexmedetomidine; the third, 83 mg/kg/min morphine; and the fourth was a control group. The rats
were measured motor coordination and pain reﬂexes by using rotarod, accelerod, hot plate, and tail
ﬂick tests.
Results: At all the tested speeds, the midazolam-injected rats remained on the rotarod longer than did
the dexmedetomidine-injected rats. Furthermore, in the 10-minute accelerod test, the midazolam-
injected rats remained for a longer duration than did the dexmedetomidine-injected rats. The latency
time for the hot plate test was signiﬁcantly higher at 10 minutes and 20 minutes in the dexmedeto-
midine group than in the midazolam group. Further, the latency time at 10 minutes for the tail ﬂick test
was greater in the dexmedetomidine group than in the midazolam group.
Conclusions: In this rat model, midazolam results in faster recovery of motor coordination performance
when compared with dexmedetomidine.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Dexmedetomidine and midazolam are known to be excellent
drugs for sedation/anesthesia. Dexmedetomidine is a highly selec-
tive α2-adrenergic agonist; it is both a sedative and an analgesic
agent.1 Midazolam is another commonly used intravenous seda-
tive agent; midazolam’s metabolites have relatively long half-lives,
particularly after repeated administration, its use may lead to
prolonged sedation and induce hangover effects such as cognitive
and psychomotor impairment.2,3
To our knowledge, no study on comparative motor perform-
ance and analgesic efﬁcacy has satisfactorily investigated the
effects of these 2 drugs. Therefore, in this study, we aimed to
compare the sedative and analgesic effects and the recoveryr Inc.
dogan, MD, Department of
School of Medicine, Malatya,
S. Aydogan).
Open access under CC BY license.proﬁles of midazolam and dexmedetomidine in a rat model by
conducting motor coordination tests (rotarod-accelerod test) and
by evaluating the analgesic response times by conducting hot plate
and tail ﬂick tests.Methods
This study was approved by the Inonu University Research
Animals Ethics Committee of Inonu University, Malatya, Turkey
(Acceptance No. 2012/A-55).
Animals and laboratory
This animal experiment was conducted in accordance with EC
Directive 86/609/EEC. Thirty-two male Sprague-Dawley albino rats
(age 10–12 weeks; weight, 200–260 g) were obtained from the
Inonu University Laboratory Animal Research Center and placed
in a temperature- and humidity-controlled room (211C [721C];
60% [5%] humidity) with a 12-hour light:dark cycle. Food and
water were provided ad libitum, except during the test periods.
The rats were randomly divided into 4 groups (n ¼ 8 per group)
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saline (control), morphine hydrogen chloriden midazolam†, and
dexmedetomidine‡ .
Drug application
The rats were anesthetized by IP administration of 100 mg/kg
ketamine§ and 10 mg/kg xylazine║. The right jugular vein was
catheterized for drug and vehicle administration. Morphine hydro-
chloride, midazolam, and dexmedetomidine were administered in
a saline solution as 1 mL. Morphine hydrochloride and midazolam
were administered at 83 mg/kg/min and dexmedetomidine was
given at 1 mg/kg/min. The dosage scheme was chosen according to
that used in previously reported related successful studies.4–6
There was sufﬁcient time between the anesthesia and testing of
the test drugs. However, this washout period was more different
among the rats. For standardization of the experimental design,
ﬁrst of all the zero point was determined according to the sensory-
motor responses as described previously.7
Sensory processing was evaluated in paw withdrawal response
to forceps pinch of the lateral foot/toe. The pinch was limited to
a maximum of 1 second to avoid direct paw tissue trauma. Sen-
sory responses were evaluated by the withdrawal reﬂex or vocal-
ization to pinch and quantiﬁed as 0. Motor function was quantiﬁed
as 0 ¼ normal dorsiﬂexion ability and normal walking without
curled toes.
Experimental procedures in the rotarod and accelerod tests
Rotamex 4/8 system (Columbus Instruments, Columbus, Ohio)
was used for the rotarod and accelerod tests. Trials were carried
out to select the test group 24 hours before the experiment. The
rats were placed on a rotating rod, and the test was performed at
different rotation speeds (for a maximum of 5 minutes per speed
level), beginning at the slowest speed of 5 rpm, followed by
10 rpm, and then with 10-rpm increments in the speed up to
40 rpm, while measuring the duration for which each animal
could stay on the rod at a given rotation speed. Animals that could
remain on the rod for 2 successive trials were selected for drug
testing. Results were expressed as the percentage of animals
that succeeded in remaining on the rod until the cut-off time
(300 seconds) was reached. The total time that the rats ran on the
rotarod, the time to falling from it, and all other set-up parameters
were recorded. The accelerod test was set up with acceleration
from 1 to 79 rpm within 4 and 10 minutes. Because several rats
were tested in a single session, each rat was allowed to rest for
approximately 5 minutes between the different speed tests; this
helped to reduce the animal’s stress and fatigue.8
Measurement of analgesia
Acute thermal pain was modeled by the hot plate and tail ﬂick
tests, which are 2 methods to measure thermal analgesia in
rodents.
Experimental procedures of the hot plate test
The surface of a hot plate (Columbus Instruments) was heated
to achieve a constant temperature of 501C (70.51C), which was
ascertained using a built-in digital thermometer. The time (inn Trademark: Morphines (Galen, Istanbul, Turkey).
† Trademark: Dormicums (Dem, Melsungen, Germany).
‡ Trademark: Precedexs (Hospira, Lake Forest, Illinois).
§ Trademark: Ketalars (Pﬁzer, Istanbul, Turkey).
║ Trademark: Rompuns (Bayer, Toronto, Ontario, Canada).seconds) between the placement of the rats on the plate and the
onset of shaking, paw licking, and jumping off the plate was
recorded as the response latency. To avoid tissue damage, 60
seconds was set as the cut-off time after which the rats were
returned to the cage, regardless of whether or not a response was
observed.9 The baseline was considered to be the mean reaction
times obtained at 0 and 30 minutes before administration of the
drugs and was deﬁned as the normal reaction of the animal to
temperature stimulus. Latency in the hot plate test was measured
at 0, 10, 20, and 60 minutes after drug injection. No further
nociceptive thresholds were measured until full recovery occurred
from the effects of the general anesthetic.
Experimental procedures in the tail ﬂick test
Antinociception and thermal analgesia were assessed using the
radiant heat tail ﬂick test apparatus (Type 812; Columbus Instru-
ments) as previously described.10 Brieﬂy, the rats were placed in
transparent hard plastic tubes, and the tests were repeated 3 times
(with a 15-second interval) at each time point. The mean tail ﬂick
latency obtained from measurements of 3 pre-drug trials repre-
sented the individual baseline latency. Only those animals showing
tail ﬂick latencies ranging from 2 to 5 seconds before the treat-
ment were used in the experiments. Immediately after baseline
assessment, drugs or saline was injected into the rats according to
the study protocol. Measurement of responses were taken at time
zero, 10, 20, and 60 minutes after treatment of the animals with
drugs by application of pressure from the analgesiometer onto
their tail (1 cm from the tip of the tail). The cut-off time was set at
10 seconds to avoid tissue damage. The timing of the drug
injections was adjusted according to those used in previously
reported related successful studies in rodents.11,12
Statistical analysis
For detecting even minor effects, the required sample sizes
used in this experiment were identiﬁed using statistical power
analysis. The sample sizes necessary for a power of 0.80 were
estimated using NCSS software (NCSS LLC, Kaysville, Utah). Data
were analyzed using the SPSS software program for Windows,
version 21.0 (IBM Corp, Armonk, New York). The assumption of
normal distribution was conﬁrmed using the Kolmogorov-Smirnov
test. Homogeneity of variance was tested by Levene's statistic.
When the assumptions of a normal distribution and homogeneity
of variance were provided, 1-way analysis of variance was used to
compare the investigated variables among the groups. Multiple
comparisons were made by Tukey's honestly signiﬁcant difference
test when the variance was homogeneous; otherwise, Tamhane’s
T2 test was performed for multiple comparisons. The results are
expressed as mean [SD] for hot plate and tail ﬂick tests, jugular
catheter time, drug onset time, and recording onset time. The
Kruskal-Wallis H test was used when the assumption of normality
was not provided. The Mann Whitney U test with Bonferroni
correction was used for multiple comparisons. The values were
given as median (minimum–maximum) for rotarod and accelerod
results, ketamine dose, and xylazine dose. Statistical signiﬁcance
was set at P o 0.05.Results
Catheterization and drug measurements
The hypnotic effects of dexmedetomidine, midazolam, and
morphine were observed within 30 seconds, and none of the rats
moved spontaneously while the 3 drugs were being infused.
Table I
Initial anesthesia dose and pretest time. Values are presented as median (minimum-maximum) or mean [SD].
Variable Midazolam (n ¼ 8) Dexmedetomidine (n ¼ 8) Morphine (n ¼ 8) Control (n ¼ 8)
Ketamine dose (mg) 30 (30–33) 30 (30–32) 30 (30–33) 30 (30–33)
Xylazine dose (mg) 4 (3–5) 4 (3–5) 4 (4–4) 4 (3–5)
Jugular catheter time (min) 14.50 [0.92] 14.25 [1.28] 14 [1.06] 14.12 [1.24]
Drug onset time (min) 26.87 [2.29] 26.75 [2.12] 27.25 [2.37] 27.50 [2.50]
Recording onset time (min) 148.75 [13.15]*,† 123.25 [9.16]* 112.37 [9.08]* 58.75 [16.48]
Wash-Out time (min) 198.57 [17.09]*,† 170.25 [12.10]* 150.30 [15.24]* 100.75 [19.21]
nVersus control (P o 0.05).
†Versus morphine (P o 0.05).
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doses among the groups (P 4 0.05) (Table I). Drug onset and
jugular catheter application times did not differ signiﬁcantly
among the groups (P 4 0.05) (Table I). The onset time was
found to be higher in the midazolam-treated group than in the
dexmedetomidine group (P o 0.05) (Table I).
Measurement of sedation
There was no difference among the groups in the basal rotarod
performance measurements (P 4 0.05) (Table II). A difference was
observed only at 30 rpm between the midazolam and control
group during the test (P o 0.016) (Table II). In the rotarod test, the
duration of time for which each animal was able to stay on the rod,
was found to be higher in the midazolam-treated group than in
the dexmedetomidine group at all tested speeds (P o 0.016)
(Table II). The dexmedetomidine and control groups showed a
signiﬁcant difference at all measurement points during the rotarod
test (P o 0.016) (Table II). The duration of time for which the
animals were able to remain on the rod was lower in the
dexmedetomidine group than in the control group at all tested
speeds in the rotarod test (P o 0.016) (Table II). For accelerod
performance, there was no signiﬁcant difference among the
groups in the basal performance measurements (P 4 0.05)
(Table II). After the drug treatment, the duration for which each
animal could stay on the rod during the accelerod test was
signiﬁcantly increased in the midazolam group than in the
dexmedetomidine group at the 10-minute test (P o 0.016)
(Table II). During the accelerod test, differences were observedTable II
Rotarod and accelerod results with or without (baseline) drugs. The data are presented
Variable Midazolam (n ¼ 8)
Baseline rotarod test (sec)
5 rpm 300 (247–300)
10 rpm 300 (136–300)
20 rpm 180 (90–300)
30 rpm 45 (28–156)
40 rpm 17 (10–43)
Rotarod test with drugs (sec)
5 rpm 224 (145–300)†
10 rpm 198 (68–300)†
20 rpm 144 (98–300)*,†
30 rpm 38 (23–179)*,†
40 rpm 14 (10–57)†
Baseline Accelerod test (sec)
4 (min) 91 (21–219)
10 (min) 142 (58–300)
Accelerod test with drugs (sec)
4 (min) 102 (92–125)*
10 (min) 163 (136–359)†
nVersus control (P o 0.016).
†Versus dexmedetomidine ( P o 0.016).between the dexmedetomidine group and control group for all
measurements (P o 0.016) (Table II), whereas between the
midazolam and control groups, differences were observed only
at 4 minutes (P o 0.016) (Table II).
Measurement of analgesia
Morphine showed longer latency times when compared with
midazolam, dexmedetomidine, and control groups in the hot plate
test (P o 0.016) (Table III). Compared with the control group, the
midazolam group showed signiﬁcantly increased latency times at
0, 10, 20, and 60 minutes in the hot plate test (P o 0.016) (Table III).
At 10 minutes, the latency time of the dexmedetomidine group
was longer than that of the midazolam group (P o 0.016) (Table III).
The results of the hot plate test obtained at 10 minutes showed that
the analgesic effect of dexmedetomidine (relative to the control
group) was higher than that of midazolam (P o 0.05) (Table III).
Compared with morphine, the midazolam, dexmedetomidine, and
control groups showed more than decreased latency times at time
points in the tail ﬂick test (P o 0.05) (Table IV). Compared with
the control group, the midazolam and dexmedetomidine groups
showed signiﬁcantly increased latency times at 0, 10, 20, and
60 minutes in the tail ﬂick test (P o 0.05) (Table IV). At 0, 10, and
20 minutes, the latency times of the dexmedetomidine group were
longer than those of the midazolam group (P o 0.016) (Table IV).
The results of the tail ﬂick test obtained at 10 and 20 minutes
showed that the analgesic effect of dexmedetomidine (relative to
the control group) was better than that of midazolam (P o 0.05)
(Table IV).as median (minimum–maximum).
Dexmedetomidine (n ¼ 8) Control (n ¼ 8)
300 (288–300) 300 (149–300)
300 (148–300) 255 (131–300)
175 (75–300) 184 (94–300)
39 (15–129) 45 (17–142)
15 (10–35) 18 (10–37)
141 (110–160)* 300 (187–300)
109 (99–126)* 300 (189–300)
58 (20–117)* 215 (91–300)
10 (10–20)* 191 (71–240)
9 (6–16)* 45 (10–102)
137 (31–203) 136 (96–195)
184 (57–266) 225 (167–277)
59 (13–94)* 154 (111–198)
129 (113–136)* 223 (79–390)
Table III
Hot plate latency time results (in seconds). Data are presented as mean [SD].
Variable
(min)
Midazolam
(n ¼ 8)
Dexmetedomine
(n ¼ 8)
Morphine
(n ¼ 8)
Control
(n ¼ 8)
Baseline 0 20.6 [4.1] 19.1 [5.1] 19.5 [3.2] 18.5 [2.8]
Drug 0 22.5 [2.6]*,‡ 23,1 [1.3]*,‡ 36 [3.6]‡ 14 [5.6]
Drug 10 17.6 [1.9]*,‡ 18.6 [4.3]*,†,‡ 34.8 [4]‡ 13.8 [4.9]
Drug 20 15 [3.7]*,‡ 14.8 [4.2]*,‡ 24.7 [4.2]‡ 12.6 [5.2]
Drug 60 11.8 [3]*,‡ 11.5 [4.7]*,‡ 17.1 [4.5]‡ 11.1 [5.1]
nVersus morphine.
†Versus midazolam.
‡Versus control (P o 0.016).
M. Said Aydogan et al. / Current Therapeutic Research 75 (2013) 22–26 25Discussion
The main ﬁnding of our study is that although midazolam
exerted a faster onset recovery of motor coordination performance,
dexmedetomidine provided greater analgesic efﬁcacy and longer
motor and sensory blockades than midazolam. This result is in
agreement with a human-subjects study in which dexmedetomi-
dine was reported to have a longer recovery time than a mid-
azolam when used for sedation.13
Dexmedetomidine is the active isomer of the analgesic mede-
tomidine that binds to α-2-adrenergic receptors in an agonist
fashion with high speciﬁcity. The α-2-adrenergic receptor agonists
produce varying levels of sedation, analgesia, muscle relaxation,
and anxiolysis.14 Benzodiazepines, when administered alone, have
been shown to have a hyperalgesic effect.15 Further, subcutaneous
injection of midazolam decreased the analgesia associated with
ketamine.16 Our ﬁndings emphasized the signiﬁcantly greater
analgesic status conferred by dexmedetomidine than by midazo-
lam. It is not surprising to ﬁnd that dexmedetomidine provided a
better analgesic effect than midazolam. Boehm et al17 found that
midazolam had no signiﬁcant effect on the tail ﬂick latency when
compared with baseline. In contrast, dexmedetomidine showed a
clear dose-dependent increase in tail ﬂick latency. These ﬁndings
are supported by the fact that patients treated with dexmedeto-
midine can report their pain response to health care providers as a
result of their more conscious state.18
The hot plate test is commonly used to assess narcotic analgesia.
Although the central and peripheral analgesics respond by inhibit-
ing the number of contractions provoked by chemical pain stimuli,
only the central analgesics increase the time of response in the hot
plate test, because the hot plate is a speciﬁc central antinociceptive
test in which opioid agents exert their analgesic effects via supra-
spinal and spinal receptors.19 In the hot plate test (Table III),
treatment with morphine caused a marked increase in the latency
time of the animals compared with other study drugs. It is because
morphine shows antinociceptive efﬁcacy through opioid receptor-
mediated mechanisms achieved at doses that had no signiﬁcantTable IV
Tail ﬂick latency time results (in seconds). Data are presented as mean [SD].
Variable
(min)
Midazolam
(n ¼ 8)
Dexmetedomine
(n ¼ 8)
Morphine
(n ¼ 8)
Control
(n ¼ 8)
Baseline 0 3.31 [1] 3.54 [1.1] 2.77 [1.1] 3.42 [0.9]
Drug 0 8.95 [2.7]*,‡ 9 [3.1]*,‡ 12 [2]*,‡ 3.76 [0.7]
Drug 10 8.50 [1.3]*,‡ 8.75 [2.9]*,†,‡ 11 [2]*,‡ 3.85 [0.6]
Drug 20 6.88 [1.8]*,‡ 7.62 [2.3]*,†,‡ 9.87 [1.9]*,‡ 3.86 [0.6]
Drug 60 6.1 [2.1]*,‡ 5.75 [1.9]*,‡ 8 [2]*,‡ 3.75 [0.6]
nVersus morphine.
†Versus midazolam.
‡Versus control (P o 0.05).effect on motor activity. The results of the hot plate test clearly
indicated that dexmedetomidine exerted its analgesic effect early
(within the ﬁrst 10 minutes). Furthermore, the results of the tail
ﬂick test obtained at 10 and 20 minutes showed that the analgesic
effect of dexmedetomidine (relative to the control group) was better
than that of midazolam. Therefore, the long-term analgesic effects
of dexmedetomidine could be clinically useful for sedation. How-
ever, the recovery time from motor coordination impairment was
more rapid in the midazolam group than in the dexmedetomidine
group. Thus, midazolam may allow neurologic assessments and
communication with the patient without interruption of the calm-
ing effects of sedation. The increased analgesic requirement in the
midazolam group can be considered to be a normal response of the
physiologic and compensatory mechanisms. This is consistent with
characteristics of dexmedetomidine, which include the ability to
achieve sedation while preserving patient arousability.20
Another possible explanation for this result may be related to
the dexmedetomidine dose used in this study: Only a single
concentration was evaluated. This may also be considered a
limitation of our study.Conclusions
Taken together, these results indicate that midazolam is pre-
ferred over dexmedetomidine for use in sedation applications for
recovery of motor coordination performance. Further studies are
needed to evaluate the potential of these drugs for analgesia with
psychomotor performance function.Acknowledgments
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